David Hall Joins Rho as Principal Investigator of Bioinformatics

David Hall Joins Rho as Principal Investigator of Bioinformatics

Genome informatics specialist played central role in business development activities resulting in award of more than $40M in federal contracts with bioinformatics and -omics focus

Chapel Hill, NC  ̶  July 15, 2014 - Rho, a contract research organization (CRO) focused on bringing new products to market through a full range of product development services, today announced that David Hall has joined its team as a principal investigator (PI) specializing in bioinformatics at its Research Triangle Park headquarters in North Carolina. David brings more than 12 years of experience in bioinformatics as a principal investigator, general manager, project manager, bioinformatics lead, programmer/analyst, data modeler and software engineer. 

As a principal investigator at Rho, David will serve as the group leader for bioinformatics in the consolidated Division of Allergy, Immunology and Transplantation (DAIT) application of the National Institute of Allergy and Infectious Diseases (NIAID) and of the National Institutes of Health (NIH) proposal.

David joins Rho most recently from Syngenta where he specialized in genome informatics, overseeing the development of genomic data systems and tools supporting trait gene discovery and molecular breeding. Additionally, he served as the principal investigator on two National Institutes of Health (NIH)-funded contracts focusing on bioinformatics and data coordination while at RTI International.  As one of the initial hires into the RTI International Bioinformatics Program, David played a central role in business development activities resulting in the award of more than $40M in federal contracts and grants with a bioinformatics or -omics focus.

"David's distinguished bioinformatics background combined with his leadership in genome informatics at a world-class biotechnology company make him a perfect fit for this opportunity," said Russ Helms, Ph.D., chief executive officer for Rho. "We look forward to David's contribution as the group leader of bioinformatics and to utilizing his expertise to enhance the scientific reputation of Rho and its 30-year track record of leading federally and commercially funded research," said Dr. Helms.

To learn more about Rho, please visit http://www.rhoworld.com/rho/career-center.

About Rho

Rho, a privately-held, contract research organization (CRO) located in Chapel Hill, NC, provides a full range of clinical research services across the entire drug development process. For 30 years, Rho has been a trusted partner to some of the industry's leading pharmaceutical, biotechnology, and medical device companies as well as academic and government organizations. Our commitment to excellence, our innovative technologies, and our therapeutic expertise accelerate time to market, maximize returns on investment, and lead to an exceptional customer experience. Please follow us on Twitter.

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.